Skip to main content
PRVA
NASDAQ Industrial Applications And Services

Privia Q3 Revenue $657M, Net Income Up 97%; Full-Year 2026 Guidance Raised Above High End

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Health Tech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$22
Mkt Cap
$2.861B
52W Low
$18.915
52W High
$28.82
52W Position info
16% above low
Off High info
24% below high
Rel. Volume info
2.3× avg
Market data snapshot near publication time

PRVA sits 16% above its 52-week low of $18.915 on elevated volume (2.3× avg).

Summary

Privia reported Q3 revenue of $657.0M (+13.2%) and net income of $13.5M (+96.6%), then raised full-year 2026 guidance above the high end of its prior ranges for revenue and Adjusted EBITDA.


Key Events · Earnings and Guidance · PRVA

  • Q3 Results Beat Prior Year

    Revenue of $657.0M rose 13.2% from $580.4M, operating income jumped 42.6% to $20.5M, and net income nearly doubled to $13.5M from $6.9M.

  • Guidance Raised Above High End

    Full-year 2026 revenue guidance moves to $2,500-2,550M from a prior $2,350-2,450M range, and Adjusted EBITDA to $154-157M from $145-155M — above the old high end on every key metric.

  • Balance Sheet Funds MSSP Deal

    Cash and equivalents were $446.3M with no debt at September 30, 2026; the ~$36M American Choice Healthcare MSSP acquisition closed off balance-sheet cash, and year-end cash is guided to at least $520M.

  • Montana Partnership Exits in 2027

    The Surgery Partners Montana partnership ends effective January 2027, removing 69 providers and roughly $23M of annual Practice Collections, with no material 2027 Adjusted EBITDA impact expected.


Analysis · PRVA · Industrial Applications And Services

The quarter was strong enough that Privia raised 2026 guidance above the high end of every key metric — revenue to $2.50-2.55B from a prior $2.35-2.45B range, and Adjusted EBITDA to $154-157M from $145-155M. Q3 net income nearly doubled to $13.5M on 13.2% revenue growth, and with $446.3M of cash and no debt, the $36M American Choice Healthcare MSSP purchase announced this week is funded from the balance sheet rather than new financing. The offset is the Montana partnership exit effective January 2027, which removes 69 providers and roughly $23M of annual Practice Collections but is guided to have no material EBITDA impact.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PRVA was trading at $22.00 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $2.9B. The 52-week trading range was $18.92 to $28.82. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PRVA - Latest Insights

PRVA
Nov 18, 2026, 8:38 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $25.26
Real-time Price: $25.05 info
Change: -$0.210 (-0.83%) info
Market Cap: $3.201B info
PRVA
Nov 18, 2026, 8:30 AM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $25.26
Real-time Price: $25.05 info
Change: -$0.210 (-0.83%) info
Market Cap: $3.201B info
PRVA
Nov 05, 2026, 8:50 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $23.19
Real-time Price: $25.05 info
Change: +$1.86 (+8%) info
Market Cap: $3.201B info
PRVA
Nov 05, 2026, 6:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $22.00
Real-time Price: $25.05 info
Change: +$3.05 (+14%) info
Market Cap: $3.201B info
PRVA
Nov 02, 2026, 8:30 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $21.48
Real-time Price: $25.05 info
Change: +$3.57 (+17%) info
Market Cap: $3.201B info